Autor: |
Motamed M; Department of Internal Medicine (Motamed), University of Toronto; Cardiovascular Division (Nunes, Udell), Women's College Hospital; Peter Munk Cardiac Centre (Nunes, Udell), University Health Network, Toronto, Ont., Nunes JT; Department of Internal Medicine (Motamed), University of Toronto; Cardiovascular Division (Nunes, Udell), Women's College Hospital; Peter Munk Cardiac Centre (Nunes, Udell), University Health Network, Toronto, Ont., Udell JA; Department of Internal Medicine (Motamed), University of Toronto; Cardiovascular Division (Nunes, Udell), Women's College Hospital; Peter Munk Cardiac Centre (Nunes, Udell), University Health Network, Toronto, Ont. jay.udell@utoronto.ca. |
Abstrakt: |
Competing Interests: Competing interests:: Unrelated to this work, Jacob Udell has served as a consultant or speaker for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Novavax, Novartis, and Sanofi and has received research grants from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim–Lilly, Bristol Myers Squibb, and Janssen. No other competing interests were declared. |